In a pooled analysis of 9,371 adults (median age 62, 47% female), thigh-worn accelerometry revealed curvilinear dose-response relationships between multiple step metrics and quality of life (QoL). The sweet spot for daily step volume landed at 6,561 steps/day—associated with a 0.35 SD improvement in QoL versus a 4,000-step reference. Peak cadence targets were similarly modest: 107 steps/minute for peak 1-minute effort and 74 steps/minute for peak 30-minute cadence. For fast stepping (≥100 steps/min), cardiovascular disease status mattered: CVD patients reached optimal QoL at just 4 minutes/day versus 9 minutes/day in healthy adults.
This preprint, not yet peer-reviewed, carries meaningful implications. The 6,500-step threshold sits notably below the popular 10,000-step target, reinforcing accumulating evidence—including work by Tudor-Locke and colleagues—that meaningful health returns begin well before that benchmark. The curvilinear shape is clinically important: it suggests diminishing returns and argues against prescribing ever-higher step counts indiscriminately. The CVD-specific fast-stepping finding is particularly actionable, offering a data-grounded rationale for lower-intensity step prescriptions in cardiac populations without sacrificing QoL gains. Limitations include the observational, cross-sectional design preventing causal inference, reliance on questionnaire-based QoL measures subject to recall bias, and the predominantly middle-to-older-age European cohort limiting generalizability. Whether these thresholds hold across diverse ethnicities or younger adults remains untested. Overall, this is a confirmatory-plus study—solidifying low step targets while adding nuance on cadence and CVD that prior research lacked.